SparingVision logo


See SparingVision's full profile



Founded Year


Total Funding



11 - 50



About SparingVision

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.



General Information on SparingVision

Brand name SparingVision
Company name SparingVision
Founded year 2016
Employees 11 - 50
Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.

Recent News and Activity about SparingVision

Ysios Capital Partners 10.12.2021
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

– SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Dr Mehdi Gasmi, PhD, as Chief Operating Officer (COO), as well as other senior appointments, further strengthening the SparingVision team. Mehdi Gasmi is a seasoned executive with over 25 years of experience across the gene therapy drug development field, including in ophthalmology indications. His deep ...

SparingVision news
Global Legal Chronicle 27.10.2021
Intellia Therapeutics' Acquisition of a Stake in SparingVision

Foley Hoag LLP advised Intellia Therapeutics with a team including Fr??ic Cohen (Corporate M&A), Sarah Cooleybeck (Life Science & Healt Care), Nicola Lemay (Tax M&A and Deal Advisory), Christopher Natkanski (IP&IT). Goodwin Procter advised SparingVision SAS with a team including Malcolm Bates (IP&IT). Read the full article on Global Legal Chronicle France

SparingVision news
BioPharm International 16.10.2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Intellia Therapeutics, a genome editing company developing curative therapeutics using clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein-9 (CRISPR/Cas9), announced a strategic collaboration with SparingVision, a genomic company developing treatments for ocular diseases, on Oct. 13th, 2021, in a press release. The goal of this partnership is to develop novel genomic medicines for the treatment of ocular ... 14.10.2021
SparingVision : Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Weiter zum vollständigen Artikel bei "Investegate" Analysen zu Intellia Therapeutics Inc Alle Kaufen Hold Verkaufen

BioCentury 14.10.2021
Intellia sees path to take CRISPR into eye via SparingVision

Intellia sees path to take CRISPR into eye via SparingVision Rather than building own ophthalmology pipeline, Intellia partners with French biotech for therapies against three targets By Lauren Martz, Senior Editor October 13, 2021 11:01 AM GMT

SparingVision news
FirstWord Pharma 14.10.2021
Intellia forges pact with SparingVision focused on eye diseases

Intellia Therapeutics has clinched a deal granting SparingVision exclusive rights to its in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets, the companies announced Wednesday. Intellia will also grab a 10% equity stake in SparingVision, and be eligible for milestone payments of around $200 million per product, as well as royalties on any future sales arising from the tie-up."We have been thoroughly ...